NASDAQ: BIVIBiovie Inc Stock
$1.91+0.06 (+3.24%)
Updated Oct 17, 2025
BIVI Price
$1.91
Fair Value Price
N/A
Market Cap
$14.39M
52 Week Low
$1.42
52 Week High
$75.00
P/E
-0.16x
P/B
0.76x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$17.54M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.13
Operating Cash Flow
-$19M
Beta
1.55
Next Earnings
Nov 13, 2025
Ex-Dividend
N/A
Next Dividend
N/A
BIVI Overview
BioVie Inc. is a clinical-stage biotechnology company that discovers, develops, and commercializes drug therapies. Its lead product, BIV201, is a drug approved in 40 countries to treat related complications from liver cirrhosis. BioVie was incorporated in 2013 and is based in Santa Monica, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BIVI's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
BIVI
Ranked#218 of 481
Ranked#218 of 481
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.26 | A | |
| $6.63 | A | |
| $11.55 | A |
Be the first to know about important BIVI news, forecast changes, insider trades & much more!
BIVI News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BIVI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BIVI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BIVI is good value based on its book value relative to its share price (0.76x), compared to the US Biotechnology industry average (4.96x)
P/B vs Industry Valuation
BIVI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BIVI due diligence checks available for Premium users.
Valuation
BIVI fair value
Fair Value of BIVI stock based on Discounted Cash Flow (DCF)
Price
$1.91
Fair Value
$3.92
Undervalued by
51.33%
BIVI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BIVI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.16x
Industry
-98.2x
Market
37.42x
BIVI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.76x
Industry
4.96x
BIVI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BIVI's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.5M
Profit Margin
0%
BIVI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$21.6M
Liabilities
$2.6M
Debt to equity
0.13
BIVI's short-term assets ($20.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BIVI's short-term assets ($20.70M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BIVI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BIVI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.6M
Investing
$0.0
Financing
$0.0
BIVI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BIVI vs Biotech Stocks
Biovie Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.